GSA Capital Partners’s BioXcel Therapeutics BTAI Stock Holding History

GSA Capital Partners’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-120,102	Closed	-$192K	–	1743
2025 Q4	$192K	Buy	+120,102	New	+$248K	0.02%	1426
2022 Q3	–	Sell	-1,658	Closed	-$350K	–	1535
2022 Q2	$350K	Buy	+1,658	New	+$349K	0.05%	724
2021 Q4	–	Sell	-3,709	Closed	-$1.8M	–	1430
2021 Q3	$1.8M	Buy	+3,709	New	+$1.63M	0.18%	83

Other funds holding BTAI

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

OCM

Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

GSA Capital Partners's BTAI Position: Q1 2026 in Review

GSA Capital Partners sold out of BioXcel Therapeutics (BTAI) in Q1 2026, closing a stake of 120,102 shares — an estimated $192K sold.

GSA Capital Partners first reported a position in BTAI in Q3 2021 and held it in 3 quarters. The position peaked at $1.8M in Q3 2021. 40 funds tracked by Wall St. Rank hold BTAI as of Q1 2026.

GSA Capital Partners reported no remaining BioXcel Therapeutics position as of Q1 2026 after selling out during the quarter.
GSA Capital Partners sold 120,102 BioXcel Therapeutics shares in Q1 2026, an estimated $192K.
GSA Capital Partners first reported a position in BioXcel Therapeutics in Q3 2021 and held it in 3 quarters.
GSA Capital Partners's BioXcel Therapeutics position peaked at $1.8M in Q3 2021.
40 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.